Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Analysis of pulmonary vasodilator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat.

Badejo AM Jr, Dhaliwal JS, Casey DB, Gallen TB, Greco AJ, Kadowitz PJ.

Am J Physiol Lung Cell Mol Physiol. 2008 Nov;295(5):L828-36. doi: 10.1152/ajplung.00042.2008. Epub 2008 Aug 8.

2.

Analysis of responses to the Rho-kinase inhibitor Y-27632 in the pulmonary and systemic vascular bed of the rat.

Casey DB, Badejo AM, Dhaliwal JS, Sikora JL, Fokin A, Golwala NH, Greco AJ, Murthy SN, Nossaman BD, Hyman AL, Kadowitz PJ.

Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H184-92. doi: 10.1152/ajpheart.00181.2009. Epub 2010 Apr 30.

3.

Rho kinase and Ca2+ entry mediate increased pulmonary and systemic vascular resistance in L-NAME-treated rats.

Dhaliwal JS, Casey DB, Greco AJ, Badejo AM Jr, Gallen TB, Murthy SN, Nossaman BD, Hyman AL, Kadowitz PJ.

Am J Physiol Lung Cell Mol Physiol. 2007 Nov;293(5):L1306-13. Epub 2007 Aug 31.

4.

The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat.

Pankey EA, Byun RJ, Smith WB 2nd, Bhartiya M, Bueno FR, Badejo AM, Stasch JP, Murthy SN, Nossaman BD, Kadowitz PJ.

Can J Physiol Pharmacol. 2012 Jul;90(7):825-35. doi: 10.1139/y2012-061. Epub 2012 May 16.

PMID:
22591047
5.

Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor.

Dhaliwal JS, Badejo AM Jr, Casey DB, Murthy SN, Kadowitz PJ.

J Pharmacol Exp Ther. 2009 Jul;330(1):334-41. doi: 10.1124/jpet.109.151449. Epub 2009 Apr 15.

6.

Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat.

Pankey EA, Thammasiboon S, Lasker GF, Baber S, Lasky JA, Kadowitz PJ.

Am J Physiol Heart Circ Physiol. 2013 Nov 1;305(9):H1288-96. doi: 10.1152/ajpheart.00329.2013. Epub 2013 Aug 30.

7.

Pulmonary vasodilator responses to sodium nitrite are mediated by an allopurinol-sensitive mechanism in the rat.

Casey DB, Badejo AM Jr, Dhaliwal JS, Murthy SN, Hyman AL, Nossaman BD, Kadowitz PJ.

Am J Physiol Heart Circ Physiol. 2009 Feb;296(2):H524-33. doi: 10.1152/ajpheart.00543.2008. Epub 2008 Dec 12.

8.

Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.

Pankey EA, Bhartiya M, Badejo AM Jr, Haider U, Stasch JP, Murthy SN, Nossaman BD, Kadowitz PJ.

Am J Physiol Heart Circ Physiol. 2011 Mar;300(3):H792-802. doi: 10.1152/ajpheart.00953.2010. Epub 2011 Jan 7.

9.

Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.

Badejo AM Jr, Nossaman VE, Pankey EA, Bhartiya M, Kannadka CB, Murthy SN, Nossaman BD, Kadowitz PJ.

Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H1153-9. doi: 10.1152/ajpheart.01101.2009. Epub 2010 Jul 16.

10.

Nitric oxide regulation of TP receptor-mediated pulmonary vasoconstriction in the anesthetized, open-chest rat.

Valentin JP, Bessac AM, Maffre M, John GW.

Eur J Pharmacol. 1996 Dec 19;317(2-3):335-42.

PMID:
8997619
11.
12.

Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rats.

Koshikawa S, Nishikimi T, Inaba C, Akimoto K, Matsuoka H.

J Hypertens. 2008 Sep;26(9):1837-48. doi: 10.1097/HJH.0b013e328305086c.

PMID:
18698220
13.

Role of Rho-kinase signaling and endothelial dysfunction in modulating blood flow distribution in pulmonary hypertension.

Schwenke DO, Pearson JT, Sonobe T, Ishibashi-Ueda H, Shimouchi A, Kangawa K, Umetani K, Shirai M.

J Appl Physiol (1985). 2011 Apr;110(4):901-8. doi: 10.1152/japplphysiol.01318.2010. Epub 2011 Jan 6.

14.

Influence of nifedipine, verapamil and diltiazem on pulmonary vascular resistance and vasoconstrictors in cats.

Erdemli O, Hao Q, Cai B, Lippton HL, Hyman A.

Arch Int Pharmacodyn Ther. 1994 Sep-Oct;328(2):165-79.

PMID:
7535994
15.

Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.

Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, Shimokawa H.

Heart Vessels. 2010 Mar;25(2):144-9. doi: 10.1007/s00380-009-1176-8. Epub 2010 Mar 26.

PMID:
20339976
16.

Ca2+ sensitization and Ca2+ entry in the control of blood pressure and adrenergic vasoconstriction in conscious Wistar-Kyoto and spontaneously hypertensive rats.

Behuliak M, Pintérová M, Bencze M, Petrová M, Líšková S, Karen P, Kuneš J, Vaněčková I, Zicha J.

J Hypertens. 2013 Oct;31(10):2025-35. doi: 10.1097/HJH.0b013e328362adb3.

PMID:
24107733
17.

Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats.

Jiang BH, Tawara S, Abe K, Takaki A, Fukumoto Y, Shimokawa H.

J Cardiovasc Pharmacol. 2007 Feb;49(2):85-9.

PMID:
17312448
18.

Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.

Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF.

Circ Res. 2007 Mar 30;100(6):923-9. Epub 2007 Mar 1.

19.

Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats.

Nagaoka T, Morio Y, Casanova N, Bauer N, Gebb S, McMurtry I, Oka M.

Am J Physiol Lung Cell Mol Physiol. 2004 Oct;287(4):L665-72. Epub 2003 Sep 5.

20.

Agonist-induced periodic vasomotion in rat isolated pulmonary artery.

Burke MM, Bieger D, Tabrizchi R.

Fundam Clin Pharmacol. 2011 Aug;25(4):443-51. doi: 10.1111/j.1472-8206.2010.00878.x. Epub 2010 Sep 30.

PMID:
20880385

Supplemental Content

Support Center